NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $4.08 +0.14 (+3.55%) Closing price 04:00 PM EasternExtended Trading$4.14 +0.05 (+1.35%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiff Oncology Stock (NASDAQ:CRDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$3.99▼$4.2250-Day Range$2.49▼$4.3052-Week Range$2.01▼$5.64Volume1.33 million shsAverage Volume1.21 million shsMarket Capitalization$271.44 millionP/E RatioN/ADividend YieldN/APrice Target$11.70Consensus RatingModerate Buy Company Overview Cardiff Oncology is a clinical-stage biotechnology company focused on developing personalized combination therapies for the treatment of cancer. By leveraging its proprietary OncoSignature platform, the company integrates genomic, transcriptomic and proteomic data to predict synergistic interactions between immuno-oncology agents and targeted drugs. Cardiff Oncology’s approach aims to move beyond single-agent therapies by identifying optimal regimens that address the complexity and heterogeneity of tumor biology. The company’s pipeline includes multiple combination therapy candidates in clinical trials for various solid tumors and hematological malignancies. Its lead programs explore the use of checkpoint inhibitors in tandem with small-molecule inhibitors and monoclonal antibodies, with early data demonstrating potential benefits in tumor response rates. Cardiff Oncology also collaborates with academic medical centers and contract research organizations to accelerate the design and execution of its clinical studies. Founded in 2012 and headquartered in San Diego, California, Cardiff Oncology has expanded its research and development operations across the United States. Since inception, the company has built a multidisciplinary team of scientists, clinicians and data analysts dedicated to precision oncology. In recent years, Cardiff Oncology has entered strategic partnerships to enhance its translational research capabilities, drawing on expertise in bioinformatics and molecular diagnostics. Cardiff Oncology is led by an executive team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. The company’s leadership includes veterans from major pharmaceutical and biotechnology firms, underscoring its commitment to advancing innovative cancer therapies. With a focus on personalized medicine and data-driven insights, Cardiff Oncology seeks to deliver new combination treatments that improve outcomes for patients with difficult-to-treat cancers.AI Generated. May Contain Errors. Read More Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 33% of companies evaluated by MarketBeat, and ranked 721st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCardiff Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCardiff Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.16% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently decreased by 1.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.16% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently decreased by 1.93%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.60 News SentimentCardiff Oncology has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cardiff Oncology this week, compared to 1 article on an average week.Search Interest6 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Stock News HeadlinesLadenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationJuly 9 at 6:22 AM | msn.comWhile institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the mostJuly 3, 2025 | finance.yahoo.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. July 9 at 2:00 AM | Altimetry (Ad)CRDF - Cardiff Oncology Inc Ownership - MorningstarJuly 2, 2025 | morningstar.comMCardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low OpportunityJune 27, 2025 | seekingalpha.comCardiff Oncology, Inc. (CRDF) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comCardiff Oncology to share CRDF-004 trial data on July 29June 19, 2025 | finance.yahoo.comCardiff selloff brings attractive entry point, says H.C. WainwrightJune 19, 2025 | finance.yahoo.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $4.34 at the start of the year. Since then, CRDF shares have decreased by 6.0% and is now trading at $4.08. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative net margin of 8,308.50% and a negative trailing twelve-month return on equity of 76.45%. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/08/2025Today7/09/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees20Year Founded1999Price Target and Rating Average Price Target for Cardiff Oncology$11.70 High Price Target$19.00 Low Price Target$3.50 Potential Upside/Downside+178.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.43 million Net Margins-8,308.50% Pretax Margin-8,308.50% Return on Equity-76.45% Return on Assets-62.85% Debt Debt-to-Equity RatioN/A Current Ratio6.22 Quick Ratio6.22 Sales & Book Value Annual Sales$680 thousand Price / Sales410.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book2.26Miscellaneous Outstanding Shares66,530,000Free Float61,403,000Market Cap$279.09 million OptionableOptionable Beta1.52 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CRDF) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.